Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 10/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30884756 | 1.00 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL31692120 | 0.90 | KDM4E (0.57) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL6431490 | 0.90 | KDM4E (0.57) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL31108920 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL25333675 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL31191806 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL21450331 | 0.83 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL29084683 | 0.83 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTTDP1MEN1 | |
| SCHEMBL23643822 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8799086 | 0.81 | MAPT (0.50) | ALDH1A1KDM4EMAPTTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696331-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250270227-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| WO-2024213128-A1 | ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 山东先声生物制药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| EP-4389752-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-117769555-A | Camptothecin derivative, pharmaceutical composition and application thereof | 先声再明医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023217227-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | 先声再明医药有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-6100273-A | TOPOISOMERASE INHIBITOR ANTITUMOR AGENT | GLAXO WELLCOME INC. (US) | 2000-08-08 | — | — | US | disclosed |
| JP-2000109475-A | WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE | GLAXO INC | 2000-04-18 | — | — | JP | disclosed |
| US-5559235-A | ANTITUMOR | GLAXO WELLCOME INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0540099-B1 | Water soluble camptothecin derivatives | GLAXO WELLCOME INC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0673380-A1 | WATER SOLUBLE CAMPTOTHECIN DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5342947-A | Treating alkylenedioxy-7-trihaloacetamidomethylenecamptothecin with hydrochloric or sulfuric acid to yield amine salt, treating with alkali metal hydroxide or carbonate to obtain free base | GLAXO INC. (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1994011377-A2 | WATER SOLUBLE CAMPTOTHECIN DERIVATIVES | GLAXO INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0540099-A1 | Water soluble camptothecin derivatives | GLAXO WELLCOME INC. (US) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270227-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | TOP2B, TOP2A, TOP1 | ALDH1A1 2430/4885KDM4E 4680/4885MAPT 2386/4885 |
| US-20250304717-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE | LPXN, CLSPN, SELL | ALDH1A1 1887/4885KDM4E 4452/4885MAPT 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.